Mindpeak Raises $15.3M in Series A to Expand AI-Powered Pathological Solutions
Mindpeak specializes in developing AI-based solutions for digital pathology, with a mission to revolutionize routine diagnostics in cancer care.
Company Name: Mindpeak
Location: Hamburg, Germany
Sector: AI, Digital Pathology
Funding Details: Raised $15.3 million in Series A funding. The round was led by ZEISS Ventures and InnoVentureFund, with participation from AI.FUND, the European Innovation Council Fund, and others.
Purpose of Investment: The company plans to use the funds to further enhance its product development roadmap, specifically focusing on AI-powered histopathological assessments that support clinical labs and biopharma companies globally.
Product and Innovation: Led by CEO Felix Faber, Mindpeak is a pioneer in AI-driven digital pathology solutions designed to automate tissue analysis. The company's platform assists pathologists in routine diagnostics by providing faster, more accurate assessments of histological and immunohistochemical tissue samples. This technology helps to improve diagnostic confidence and efficiency in clinical labs, which is crucial for enhancing patient outcomes in cancer care.
Mindpeak’s AI solutions have been applied in over 30,000 patient diagnoses and are used by biopharmaceutical companies to predict the effectiveness of cancer therapies, enabling more personalized and targeted treatments. The company recently expanded its product portfolio to include additional organs, biomarkers, and staining techniques to support a wider range of diagnostic needs.
About the Company: Mindpeak specializes in developing AI-based solutions for digital pathology, with a mission to revolutionize routine diagnostics in cancer care. Its innovations are geared towards supporting pathologists and biopharma companies with advanced tools that drive productivity, accuracy, and better clinical outcomes.